An interventional study of Bariatric surgery in Obese Patients With Bariatric Surgery, sponsored by Celia Bañuls. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by Celia Bañuls · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 390 studies in Obesity with a site in Spain — 95 open to participants now, 134 under way, 45 of them phase 3. Obesity · Spain.
Among the 390 studies in Obesity with a site in Spain, this one is the 237th largest by enrollment of the 332 interventional ones that give a count, is one of 23 that started in 2021, is one of 220 with no phase, and was the 336th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →95 of the 390 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Spain, United States, Germany and 1 more country
Ages 45–65 · Women only
Boehringer Ingelheim · Sites in Spain, United States, Germany and 1 more country
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Argentina and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Belgium and 7 more countries
Ages 6–11
AstraZeneca · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
390 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 24 · Phase 3 81 · Phase 4 7
First in 2001; this study’s year is marked. 23 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 124 across the 332 interventional studies, 128 across the 57 observational. Of the 208 that completed or were terminated, 26 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 390 have an industry lead sponsor. The 10 most frequent:
Celia Bañuls is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Celia Bañuls has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
33 of the studies in Obesity with a site in Spain that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07332273Phase 3Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludLevothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity. | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
Add all 33 to your calendar (.ics) → With an account.
Among the 390 studies in Obesity with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Several studies have demonstrated that bariatric surgery is effective for inducing weight loss in obese patients. In addition, the effects of this surgery on multiple associated alterations are well known, including changes in the secretion and activity of hormones involved in appetite regulation, satiety, and energy expenditure, as well as alterations in the gut microbiota composition.
However, in cases of severe obesity, recent data have challenged the prevailing view, as bacterial species associated with low microbial richness (prior to surgery) appear to change only marginally after bariatric surgery, despite significant metabolic improvements.
Our objective is to examine whether gut microbiota and gastrointestinal peptides are further impaired in severe obesity and, additionally, to explore how the microbiota relates to metabolic profile or sex, as well as whether bariatric surgery may differentially correct obesity-related intestinal microbial features.
To this end, we propose a prospective, interventional, translational clinical study involving a cohort of 60 obese patients (BMI > 35 kg/m²) undergoing laparoscopic gastric bypass surgery. Patients will be grouped according to their degree of obesity to assess potential baseline differences and to evaluate the efficacy of the intervention. Furthermore, we will investigate whether these parameters differ according to metabolic profile or sex.
Body composition and nutritional status will be assessed, along with cardiovascular risk factors and comorbidities (hypertension, obstructive sleep apnea syndrome, dyslipidemia, type 2 diabetes mellitus, and insulin resistance). Gastrointestinal hormones (ghrelin, GIP, GLP-1, PYY, CCK, and leptin) will be measured in serum using Luminex XMAP technology. The content and diversity of the gut microbiota will be analyzed (16S rRNA amplicon sequencing and shotgun metagenomic sequencing using Illumina MiSeq technology) in stool samples collected before and 6-12 months after surgery. Additionally, individualized dietary follow-up and assessment of participants' quality of life will be conducted.
Obesity and type 2 diabetes mellitus (T2DM) continue to increase worldwide and are strongly associated with adverse metabolic and cardiovascular outcomes. Bariatric surgery, particularly laparoscopic gastric bypass (LGB), remains the most effective therapeutic strategy for substantial weight reduction, glycemic improvement, and favorable modulation of gastrointestinal hormones, bile acids, and gut microbiota. Nevertheless, the mechanisms explaining heterogeneous metabolic responses-especially in individuals with severe, morbid, or extreme obesity-remain insufficiently elucidated. In particular, gut microbial diversity, microbial gene richness, and related inflammatory pathways appear to contribute to metabolic health, yet their behavior in severe obesity and their evolution following bariatric surgery remain poorly characterized.
To address these gaps, the investigators designed a prospective, interventional, comparative, and translational clinical study including 60 obese individuals scheduled for bariatric surgery at a single tertiary hospital. Participants will be consecutively recruited according to strict inclusion and exclusion criteria and classified by degree of adiposity (severe, morbid, or extreme obesity), metabolic phenotype (metabolically healthy or metabolically abnormal obesity), and sex.
Prior to the surgical intervention, a structured dietary protocol will be implemented. Participants will receive an individualized hypocaloric diet tailored to nutritional requirements, with a macronutrient distribution of 55% carbohydrates, 30% fats, and 15% proteins. During the two weeks preceding surgery, a very low-calorie diet based on Optisource® sachets will be administered in three daily intakes. Postoperative dietary progression will follow standardized clinical guidelines, with close monitoring to support weight reduction and metabolic stabilization. Follow-up evaluations will occur at 1, 6, and 12 months after surgery.
All participants will undergo comprehensive baseline and longitudinal assessments, including: evaluation of nutritional status; anthropometric measurements; body composition and basal metabolism; cardiovascular risk factors; metabolic comorbidities; and exclusion of secondary causes of obesity. Analytical parameters will include fasting plasma glucose, lipid profile (triglycerides, HDL-cholesterol), blood pressure, markers of hepatic and renal function, and additional biochemical indices relevant to obesity and T2DM risk stratification. Gut microbiota profiling will be conducted to evaluate microbial composition, diversity, and gene richness. Gastrointestinal hormone analyses will quantify circulating incretins and appetite-regulating peptides, including GLP-1, PYY, and ghrelin, to explore their association with postoperative metabolic outcomes. Oxidative stress and inflammatory parameters will be also assessed in order to stratify cardiovascular risk before and after induced weight loss after bariatric surgery.
Statistical analyses will be performed using SPSS 17.0. Categorical variables will be summarized with frequency distributions and percentages. Quantitative variables will be described using mean, range, and standard deviation, with normality assessed via the Kolmogorov-Smirnov test. Between-group comparisons (sex, metabolic phenotype) will employ unpaired t-tests or Mann-Whitney U tests; comparisons across obesity categories will use ANOVA. Longitudinal changes following surgery will be evaluated with repeated measures ANOVA or paired t-tests. Correlations will be analyzed using Pearson or Spearman methods, and logistic regression models will be developed to identify predictive factors for specific metabolic responses.
This study aims to determine whether gut microbiota alterations are directly linked to metabolic abnormalities across obesity phenotypes and whether bariatric surgery elicits differential microbial and hormonal responses according to degree of adiposity and sex. It further explores whether gastrointestinal peptides and other peripheral biomarkers can refine obesity phenotyping and enhance individualized clinical management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo bariatric surgery if they meet the inclusion criteria and are willing to participate in the study.
Procedure: Bariatric surgery
Bariatric surgery according to surgeon's assessment.
Also known as: Roux en-Y bypass, sleeve gastrectomy, Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S)
Analyze the changes in the diversity of the intestinal microbiota after bariatric surgery.
To assess the alpha-diversity of the intestinal microbiota, defined as the average diversity of species in an ecosystem, the Shannon index will be used. The results are interpreted as follows: values less than 2 are considered low in diversity and values greater than 3 are high in species diversity.
Time frame: 5 years
Assess differences in the diversity of the intestinal microbiota after bariatric surgery depending on the surgical procedure (Roux-en-Y gastric bypass vs sleeve gastrectomy vs SADI-S).
To assess the beta-diversity of the intestinal microbiota, defined as the average diversity of species in an ecosystem, the Bray-Curtis index will be used. The results are interpreted as follows: values less than 2 are considered low in diversity and values greater than 3 are high in species diversity.
Time frame: 5 years
Evaluate the differences in the diversity of the intestinal microbiota depending on whether patients present metabolically healthy obesity (MHO) or metabolically unhealthy obesity (MUHO) before surgery
To asses the differences in alpha-diversity of the intestinal microbiota in both groups, it will be evaluated whether there are significant differences between the Shannon indices of the two groups. The classification of patients between MHO and MUHO will be carried out using the following criteria: MUHO will be considered when patients with obesity present ≥2 metabolic abnormalities, and MHO with ≤1 metabolic abnormalities; the following cardiovascular risk factors are considered metabolic abnormalities: elevated blood pressure (defined as either SBP ≥130 mm Hg, DBP ≥85 mm Hg, or treatment with antihypertensive medications), elevated triglycerides (as fasting triglyceride concentration ≥1.7 mmol/l), low HDL-C levels (defined as HDL-C \<1.04 mmol/l, in men, \<1.29 mmol/l/l in women, or treatment with lipid-lowering medications), dysglycemia (fasting plasma glucose 5.6 to 6.9 mmol/l, and/or and insulin resistance as HOMA-IR \>3.8).
Time frame: 5 years
Evaluate significant changes in body fat mass percentage after bariatric surgery.
Percentage of body fat mass will be measured by bioelectrical impedance. It is considered to be high when ≥25% in men and ≥30% in women. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Assess significant changes in high-sensitivity C-reactive protein (hs-CRP) as an inflammatory parameter after bariatric surgery.
Participants will be considered to have achieved an improvement in high-sensitivity C-reactive protein levels if they normalize its value (normality values defined between 0 and 1.69mg/dl).
Time frame: 3 years
Evaluate significant changes in C3 protein as an inflammatory parameter after bariatric surgery.
Participants will be considered to have achieved an improvement in C3 protein if they normalize its value (normality values defined between 81 and 157mg/dl).
Time frame: 3 years
Evaluate significant changes in interleukin 1-beta (IL-1B) levels as a pro-inflammatory molecule after bariatric surgery.
IL-1B levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Evaluate significant changes in interleukin 6 (IL-6) levels as a pro-inflammatory molecule after bariatric surgery.
IL-6 levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Evaluate significant changes in tumor necrosis factor alpha (TNF-alpha) levels as a pro-inflammatory molecule after bariatric surgery.
TNF-alpha levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Assess significant changes in superoxide dismutase (SOD) levels after bariatric surgery.
Superoxide dismutase levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Analyze the significant differences between metabolomic profile before and after bariatric surgery, and between different surgery procedures (Roux-en-Y gastric bypass vs. sleeve gastrectomy).
NMR spectra will be used to obtain spectra from serum samples from the cohort. In order to evaluate if there will be significant differences after the dietetic intervention, a PLS-DA model for discrimination between basal and post intervention levels will be performed. Scores plots will be calculated with a 95% confidence interval.
Time frame: 3 years
Evaluate if there is a significant reduction after bariatric surgery in total ROS levels.
Total ROS levels will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Assess if there is a significant reduction after bariatric surgery in glutathione levels.
Total glutathione levels will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Analyze if there is a significant change after bariatric surgery in total free radicals levels.
Total free radicals will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Analyze if there is a significant reduction after bariatric surgery in mitochondrial ROS production.
Mitochondrial ROS production will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Evaluate if there is a significant change after bariatric surgery in superoxide levels.
Superoxide content will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Evaluate if there is a significant improvement after bariatric surgery in mitochondrial membrane potential.
Mitochondrial membrane potential will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Identify and assess the differences in metabolic pathways of gut microbiota after bariatric surgery.
Genetic markers of inflammation and metabolic pathways will be analyzed from the faeces samples, in order to identify different clusters of these pathways and determine the potential functions of gut microbiota. For that purpose, transcriptome will be quantified with nanostring techology. The relative quantity of gene expression (fold change) of each gene will be calculated with the comparative 2-ΔΔCT method, and significant differences will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 5 years
Analyze if there is a significant reduction after the bariatric surgery in adipsin levels.
Adipsin levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Assess significant changes in plasmatic resistin levels as an inflammatory parameter after surgical intervention.
Resistin levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Analyze if there is a significant change after the bariatric surgery in leptin levels.
Leptin will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Evaluate significant reductions in Plasminogen activator inhibitor-1 (PAI-1) as an inflammatory parameter after the bariatric surgery.
PAI-1 levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Assess if there is a significant change after the bariatric surgery in ghrelin levels.
Ghrelin will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Assess significant changes in serum Glucagon-like peptide-1 (GLP-1) levels after the bariatric surgery.
GLP-1 levels will be assessed using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Assess if there is a significant improvement after bariatric surgery in peptide YY (PYY) levels.
PYY levels will be assessed using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Evaluate significant changes in serum gastric inhibitory polypeptide (GIP) levels after the bariatric surgery.
GIP levels will be assessed using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Analyze if there is a significant improvement after bariatric surgery in cholecystokinin (CCK) levels.
CCK levels will be assessed using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.
Time frame: 3 years
Plan to share: No
Ran from Mar 2021 to primary completion in Jan 2025, 46 months.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 46 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Celia Bañuls